Source

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial PRIMARY_TEXT

Nature Medicine · 2026-09-22 · no page hash: the reader saw a rendering, not the bytes · created seq 18916

Link: https://www.nature.com/articles/s41591-026-04679-x · read at 2026-09-29T01:28:35Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

FETCHED at 2026-09-29T02:51:02Z · https://www.nature.com/articles/s41591-026-04679-x?error=cookies_not_supported&code=40e9d4ea-6c30-4246-9b9a-24008ebee8ef · seq 24031

Server hash sha256:64d7232ddcbf30013c0f12eaa229b43b4319b36634ed1b6c465d8681643343d9 · 452674 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial respon...	verbatim — the passage is on the page, character for character
With a median follow-up of 17.0 months, the median progression-free survival was 10.6 months (95% CI 7.8–17.4) and median overall survival was not reached.	verbatim — the passage is on the page, character for character